-Reuters
Jefferies Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $120
Jefferies analyst Akash Tewari maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $100 to $120.
Related Posts
Beyond Apple’s Keynote, Here’s How To Yield $500 Per Month From Its Stock
As Apple Inc (NASDAQ:AAPL) hosts its WWDC 2023 keynote, spotlighting new tech and products such as the 15-inch…
Piper Sandler Maintains Overweight on ON Semiconductor, Raises Price Target to $85
Piper Sandler analyst Harsh Kumar maintains ON Semiconductor (NASDAQ:ON) with a Overweight and raises the price target from $75 to $85.
Can A Nuclear Spaceship Get Us To Mars Quicker? Lockheed Martin To Test Out Model In Space By 2027
On Wednesday, Lockheed Martin Corp (NYSE:LMT) announced a new contract with the U.S. Department of Defense to develop…